000117143 001__ 117143
000117143 005__ 20240319080953.0
000117143 0247_ $$2doi$$a10.3390/jcm11030600
000117143 0248_ $$2sideral$$a128201
000117143 037__ $$aART-2022-128201
000117143 041__ $$aeng
000117143 100__ $$aNavarro-Bielsa, Alba$$uUniversidad de Zaragoza
000117143 245__ $$aExperience with Cutaneous Manifestations in COVID-19 Patients during the Pandemic
000117143 260__ $$c2022
000117143 5060_ $$aAccess copy available to the general public$$fUnrestricted
000117143 5203_ $$aAfter the beginning of the SARS-CoV-2 pandemic, our dermatology department created a multidisciplinary unit to manage patients with cutaneous manifestations associated with COVID-19. With the objective of identifying skin lesions in patients with suspected COVID-19 and evaluating possible associations with systemic involvement, other infectious agents and coagulation disorders, we carried out a prospective observational study that included all patients that attended our COVID-19 dermatology clinic with a multidisciplinary protocol. A total of 63 patients (mean 34.6 years) were enrolled between May 2020 and February 2021. Overall, 27 patients (42.9%) had a positive COVID-19 test, and 74.6% had COVID-19 clinical signs. The most common skin lesion was maculopapular rash (36.5%), predominantly seen in male (54.2%) and older patients (42 vs. 30 years), followed by chilblain-like lesions (20.6%) in younger patients (13.9 vs. 20.9 years) who were predominantly barefoot at home (69.2%); these patients exhibited a tendency towards a negative COVID-19 test. A total of 12 patients (19.1%) had positive serology for herpesvirus 6 (IgM or IgG). We conclude that the COVID-19-associated skin lesions we observed were similar to those previously described. Questions as to the underlying mechanisms remain. Interferon, possibly aided by cold exposure, may cause perniosis-like lesions. Other cutaneous manifestations were similar to those caused by other viruses, suggesting that SARS-CoV-2 may reactivate or facilitate other viral infections.
000117143 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000117143 590__ $$a3.9$$b2022
000117143 592__ $$a0.935$$b2022
000117143 591__ $$aMEDICINE, GENERAL & INTERNAL$$b58 / 169 = 0.343$$c2022$$dQ2$$eT2
000117143 593__ $$aMedicine (miscellaneous)$$c2022$$dQ1
000117143 594__ $$a5.4$$b2022
000117143 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000117143 700__ $$aAbadias-Granado, Isabel
000117143 700__ $$aMorales-Callaghan, Ana Maria$$uUniversidad de Zaragoza
000117143 700__ $$aSuso-Estivalez, Catalina
000117143 700__ $$aPovar-Echeverria, Marina$$uUniversidad de Zaragoza
000117143 700__ $$aRello, Luis
000117143 700__ $$0(orcid)0000-0001-8034-3617$$aGilaberte, Yolanda$$uUniversidad de Zaragoza
000117143 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000117143 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología
000117143 773__ $$g11, 3 (2022), 600 [11 pp.]$$pJ. clin.med.$$tJournal of Clinical Medicine$$x2077-0383
000117143 8564_ $$s1216808$$uhttps://zaguan.unizar.es/record/117143/files/texto_completo.pdf$$yVersión publicada
000117143 8564_ $$s2761075$$uhttps://zaguan.unizar.es/record/117143/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000117143 909CO $$ooai:zaguan.unizar.es:117143$$particulos$$pdriver
000117143 951__ $$a2024-03-18-13:18:08
000117143 980__ $$aARTICLE